Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;27(1):16-23.
doi: 10.1177/1049909109345145. Epub 2009 Sep 10.

Methylphenidate side effects in advanced cancer: a retrospective analysis

Wael Lasheen  1 , Declan Walsh, Fade Mahmoud, Mellar P Davis, Nilo Rivera, Dilara Seyidova Khoshknabi
Affiliations

Methylphenidate side effects in advanced cancer: a retrospective analysis

Wael Lasheen et al. Am J Hosp Palliat Care. 2010 Feb.

Abstract

Introduction: Methylphenidate (MP) is often recommended for symptom control in advanced cancer. Little is known about its side effects in frail adults.

Objectives: To evaluate MP-associated symptoms or side effects (S/E).

Methods: Data was collected from 2 published prospective cohort series and a phase 2 study of MP for symptom control in advanced cancer. All 3 reports had identical dosing schedules and symptom assessments. Initial MP doses were 10 mg/d (5 mg at 8 AM and at 12 noon) titrated up to a maximum of 30 mg/d. Depression, fatigue, and symptoms identified as possible MP S/E were evaluated for presence (prevalence) and for severity (using categorical scales) before MP (day 0) and on days 3, 5, and 7 thereafter. The categorical scale used was none, mild, moderate, and severe.

Results: 62 patients were enrolled. Fifty completed 7 days of MP with a median age of 69 (range 30-90) years. Thirty-five received MP 10 mg/day. Most (96%) had improvement in depression and/or fatigue. Among the 62 patients, new symptom prevalence throughout the study was agitation (16%), insomnia (16%), dry mouth (15%), nausea (10%), tremors (6%), anorexia (5%), headache (3%), palpitations (2%), and vomiting (2%). Patients could have more than 1 symptom simultaneously. Seven (11%) withdrew due to MP S/E. Some symptoms present before MP showed significant improvement during MP therapy.

Conclusions: (1) Treatment with MP (10-20 mg/d) in advanced cancer is well tolerated. (2) S/E symptoms with MP appeared to improve spontaneously despite continued MP therapy. (3) Depression and fatigue improved at doses lower than those recommended in other clinical conditions. (4) MP improved depression and fatigue, and some secondary symptoms associated with them. Methylphenidate (MP) appears safe when used in the treatment of depression and fatigue in advanced cancer.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
COLLECTION SHEET USED FOR ALL THREE STUDIES
FIGURE 1
FIGURE 1
COLLECTION SHEET USED FOR ALL THREE STUDIES
FIGURE 1
FIGURE 1
COLLECTION SHEET USED FOR ALL THREE STUDIES
See this image and copyright information in PMC

References

    1. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc. 2000;75(7):711–21. - PubMed
    1. Volkow MD, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002;6(Suppl 1):S31–43. - PubMed
    1. Rozans M, Dreisbach A, Lertora JLJ, et al. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol. 2001;20:335–9. - PubMed
    1. Homsi J, Walsh D, Nelson K, Sarhill N, LeGrand S, Davis M. Methylphenidate for depression in hospice practice: A case series. Am J Hosp Palliat Care. 2000;17:393–398. - PubMed
    1. Sarhill N, Walsh D, Nelson K, Homsi J, LeGrand S, Davis M. Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot study. Am J Hosp Palliat Care. 2001;18:187–192. - PubMed

MeSH terms

Substances